AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 25 Aug - Akums will attend Ashwamedh–Elara India Dialogue 2026 on 2 September 2026 in Mumbai.
Source: Bse
Akums Drugs and Pharmaceuticals Limited (AKUMS)
Large CapPharma stocks · Large cap · NSE
Akums Drugs and Pharmaceuticals Limited, incorporated in 2004, is a CDMO and branded formulations player with technologically advanced manufacturing capabilities across various dosage forms. It has expanded into Asian and European markets, with a focus on R&D and operational efficiency.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals17 Oct 2026 · screener
Latest result16 Aug, 12:30 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
75BullishSMA20 +3.4% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 59
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
AKUMSD candles · FIT view+38.0%Latest close ₹709.55 on 2026-10-19
Bar
-3.0%
RSI
34
MACD hist
-11.74
52W pos
70%
2026-10-19O ₹731.45H ₹739.40L ₹704.50C ₹709.55Vol 5.0L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
AKUMSNifty PharmaNifty 500
- AKUMS
- +4.9%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +10.5 pp
Chart stats
19 Oct 2026- From 52W high
- -15.4%
- 52W range position
- 70%
- ATR (14)
- 4.2%
- Volume vs 20D
- 2.06x
- Avg traded value
- ₹19.6 Cr
- 20D price channel
- ₹704.5 - ₹838.8
₹838.8
₹409.3 - ₹838.8
₹29.7
Latest completed session
20-session average
38.3% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST42
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent80
Revenue +14.0% · PAT +55.4% YoY
Technical
Bullish75
Price trend and sector-relative-strength timing.
Valuation
Legacy model+14.9%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence74
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 80/100Rev +14% YoY · PAT +55% YoY · margin expansion · operating leverage
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,167 Cr | +14.0% | +0.8% |
| EBITDA | ₹175 Cr | +35.7% | +15.1% |
| Operating margin | 15.0% | +200 bps | +200 bps |
| PAT | ₹101 Cr | +55.4% | +24.7% |
| PAT margin | 8.7% | +230 bps | +166 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 37.80
- P/B
- 3.46
- EV/EBITDA
- 16.06
- Market Cap
- 11520.00Cr
Profitability
- ROE
- 8.45%
- ROCE
- 14.90%
- ROA
- 5.40%
- Dividend Y
- 0.14%
Growth (CAGR)
- Revenue 5Y
- 10.00%
- EPS 5Y
- 16.00%
- Revenue 3Y
- 6.00%
- EPS 3Y
- 29.00%
Balance Sheet
- Debt/Equity
- 0.05
- Interest Coverage
- 5.92×
- Altman Z
- 5.51
- Book Value
- 211.00
Cash Flow
- FCF Yield
- 2.18%
- FCF Positive Y
- 3/5
- OCF
- 1181.00 Cr
- EPS TTM
- 18.53
Shareholding
- Promoter Hold
- 75.26%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 75%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 4,359+5.9% vs prev
Net Profit
₹ CrLatest: 256-25.6% vs prev
Return on Equity
%Latest: 7.7-31.6% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 34. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~3.3% over last month) — short-term momentum positive.
- RSI(14) at 34 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 15% off 52W high · 73% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
88
RS percentile
Stage 2 UptrendEstablished S2
1M return
-9.5%
3M return
+4.9%
6M return
+34.2%
1Y return
+55.2%
RS 1D
0
RS 20D
-3
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 10.9% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +6.9%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
13 Apr 2026
S2 age
134 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 163.7-1.99%
RS vs Nifty 500164
Valuation & peers
U-Score 42 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 42 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation6/30
Growth15/25
Quality1/20
Balance Sheet10/15
Cash Flow5/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
42
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
42/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 14.9%.
- Balance sheet contributes 10/15 to the score.
Main drags
- Quality is weaker at 1/20; verify the latest quarterly trend.
- Valuation is weaker at 6/30; verify the latest quarterly trend.
- Cash flow is weaker at 5/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
37.8
PB
3.5
EV/EBITDA
16.1
ROE
8.4%
ROCE
14.9%
FCF Yield
2.2%
Debt/Equity
0.1
MoS
+14.9%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
42
Previous: 42
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+14.9%
Previous: +14.9%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
36
39
39
39
39
39
38
40
42
42
42
42
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹296.6
-139.2% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹833.85
+14.9% MoS
PEG
1.78
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
AARTIPHARM
Micro
Aarti Pharmalabs Limited
Pharmaceuticals
match 162
31
37.3
8.6%
+21%
OVERVALUED
SYNGENE
Small
Syngene International Limited
Pharmaceuticals
match 157
29
52.7
7.8%
-1179%
OVERVALUED
COHANCE
Small
Cohance Lifesciences Limited
Pharmaceuticals
match 155
23
165.0
4.9%
-4672%
OVERVALUED
DCAL
Small
Dishman Carbogen Amcis Limited
Pharmaceuticals
match 154
41
131.0
1.6%
-215%
WATCHLIST
DIVISLAB
Large
Divi's Laboratories Limited
Pharmaceuticals
match 154
43
81.5
16.5%
-485%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-06-03T03:38:38.926Z
Management commentary snapshot
Akums reported strong Q4 FY26 performance with 9.7% YoY revenue growth and 61.6% YoY Adj EBITDA growth, driven by CDMO momentum. FY26 revenue grew 5.8% YoY, with Adj EBITDA up 13.3% YoY, despite H1 challenges from soft API prices and muted domestic volumes.
The company demonstrated resilience in FY26, with strong H2 performance offsetting H1 headwinds. CDMO business is a key driver, supported by new facilities and a multi-year European contract. While API losses and high finance costs impacted PAT, margin expansion is expected from improved mix and operating leverage. Inorganic growth is also on the radar.
Current business mix
Revenue by vertical (FY26)
Latest issuer-disclosed distribution across 5 reported categories.
CDMO80.0%
Domestic Branded Formulation10.2%
API4.2%
International Branded Formulation3.3%
Trade Generics2.3%
Growth engines
Domestic CDMO Business
PositiveSustained momentum in domestic CDMO business, driven by healthy volumes and greater utilization of new facilities.
Multi-year European CDMO Contract
PositiveSuccessful execution of multi year European CDMO contract, with supplies expected to commence from FY28 for at least 5 more years.
Exports Expansion
PositiveExpansion of exports operations across Europe, Asia and Africa markets to accelerate growth.
Zambian Facility
PositiveCommissioning of the Zambian facility, with JV to procure medicines worth USD 25 million per annum from Akums for FY27 and FY28.
Capacity and execution
New Injectable Facility
CompletedAll lines of new Injectable facility now operational.
Zambian Manufacturing Plant
PlannedZambia plant to commence operations during FY 29.
New Oncology and Steroid Lines
PlannedNew lines expected to go live in FY 27 include new Oncology line and steroid line among others.
EU GMP Certifications
PlannedPlan to have ~5 plants EU GMP certified by FY 28.
Tailwinds
CDMO Volume Momentum
PositiveDuring the second half, Akums delivered strong operational performance driven by volume momentum in our CDMO business.
Cost Optimization & Margin Improvement
PositiveGross margins also improved led by our strong focus on cost-optimization.
Strengthening Market Positioning
PositiveGiven the outperformance vis-à-vis the overall market, we managed to significantly strengthen our market positioning.
Product & Geographical Mix Improvement
ExpectedMargin trajectory expected to strengthen as product and geographical mix improves and operating leverage further builds up.
Headwinds
API Price Erosion
Ongoing, but stabilizingThe operating environment through the first half was adverse - characterized by sharp erosion in API prices. API prices remained soft though initial signs of stabilization.
Muted Domestic Volume Growth
OngoingProlonged phase of low volume growth in the domestic market; IPM MAT Mar ‘26 volumes grew less than 1%*.
Risk radar
API Segment Losses
MaterialAPI losses continued in FY26, and erosion in API prices was responsible for degrowth across these segments.
High Finance Costs
MaterialFinance Cost Q4 FY26: 24 cr (vs 5 cr YoY), FY26: 94 cr (vs 35 cr YoY).
PAT Decline
MaterialPAT Q4 FY26: 81 cr (-45.6% YoY), FY26: 256 cr (-25.4% YoY).
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
The company explicitly highlights a challenging H1 FY26 followed by strong operational performance in H2 FY26, driven by CDMO volume momentum. This necessitates both QoQ to assess sequential recovery and YoY to evaluate overall annual growth and compare against prior year's performance.
Sector KPIs management disclosed
Domestic Formulations Volume Growth
Positive for Akums, negative for IPMAkums’ witnessed double digit volume growth though IPM MAT Mar ‘26 volumes grew less than 1%*.
EU Dossier Approvals & Dispatches
PositiveReceived 1st EU dossier approval with first commercial dispatch in Q3 FY26.
International Pipeline
PositivePipeline of 10+ formulation products; filed 2 API CEPs in Europe.
Total DCGI Approvals
PositiveTotal cumulative DCGI approvals count at 1,056 till FY26.
Management forward view
Strengthening Margins
OutlookMargin trajectory, which has been encouraging through the second half, is expected to strengthen as product and geographical mix improves and operating leverage further builds up.
Inorganic Growth Opportunities
StrategyWith a strong balance sheet, we can strategically scale up our business operations through inorganic opportunities.
Long-term Shareholder Value
CommitmentRemain committed to creating long term shareholder value and look forward to the year ahead with positivity and confidence.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| CDMO Revenue Growth | Q4 FY26 CDMO Revenue 952 cr (+13.7% YoY); FY26 CDMO Revenue 3,485 cr (+8.6% YoY). | Sustained double-digit growth and increasing contribution to overall revenue. |
| Overall Capacity Utilization | Improved to 44% for FY26. | Continued ramp-up, especially from new facilities and lines. |
| Exports Contribution & EU Approvals | 1st EU dossier approval in Q3 FY26, pipeline of 10+ formulation products. | Commencement of EU CDMO contract supplies (FY28), further EU GMP certifications, and growth in international branded formulations. |
| API Segment Profitability | API losses continued in FY26. | Stabilization of API prices and segment turning EBITDA positive. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
74Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 75th percentile of the scored universe and 65th percentile within Pharma. Main check: results consistency is weak at 53/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
37 docs text-extracted · 15 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
75th percentile
overall median 67 · Pharma: 65th pctile, median 70 · Large: 55th pctile, median 73
Evidence depth
Financial-only
37 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
53
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 75.3%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 2.1%.
- ▸Debt/equity is 0.05.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Akums Drugs and Pharmaceuticals Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Sep - Intimation of Schedule of the Institutional Investors Meets
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 16 Sep
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Aug - Intimation of Schedule of the Investors/Analysts Meet to be held on August 14, 2026
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 Aug
Source: Bse
Annual reportJul 2026
Jul 2026 · Notice And Integrated Annual Report For The Financial Year 2025-26 To Those Members Who Have Not Registered Their E-Mail ID'S 19 Jun - Akums issued AGM notice and FY2025-26 annual report; AGM on July 10, 2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Jun - Akums will attend two investor meets on June 15, 2026 in Singapore and Mumbai.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 3 Jun - Akums will attend India Investor Conference on 8 June 2026 at Grand Hyatt, Mumbai.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 9 Jun - Akums will join InsightX 2026 Virtual Conference on June 12, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 19 Jun - Newspaper Advertisements of the 22nd Annual General Meeting of the Company
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.